Colorectal Cancer
Colorectal Cancer
Advertisement
Zachary BessetteColorectal Cancer | February 23, 2024
TNT with induction chemoimmunotherapy and long-course chemoradiation may lead to high CR in high-risk, pMMR rectal cancer.
Read More
Emily MenendezColorectal Cancer | February 14, 2024
Both CD8IE and FoxP3IS showed independent prognostic value as RFS markers in bivariable and multivariable analyses.
Thierry André, MDColorectal Cancer | February 12, 2024
Nivolumab plus ipilimumab showed significant improvement in progression-free survival in patients in the first line setting.
Katy MarshallPancreatic Cancer | February 6, 2024
The ELI-002 vaccine uses T cells to identify and remove tumor cells containing KRAS G12D- or G12R-mutated cancer.
Emily MenendezColorectal Cancer | February 7, 2024
GLP-1RAs are linked to a decreased risk of CRC compared with insulin and other antidiabetic drugs.
Christopher Lieu, MDASCO GI 2024 | January 25, 2024
Dr. Lieu discusses the CIRCULATE-NORTH AMERICA trial on ctDNA status as a biomarker for risk stratification in colon cancer.
Emily MenendezASCO GI 2024 | January 23, 2024
First-line nivolumab plus ipilimumab can act as a beneficial standard-of-care option for patients with MSI-H/dMMR mCRC.
Katy MarshallColorectal Cancer | January 23, 2024
Colorectal cancer is now the leading cause of death for men and the second leading cause for women under 50 years of age.
Katy MarshallASCO GI 2024 | January 23, 2024
Prior research shows select patients with mCRC endure longer response to regorafenib while in clinical care settings.
Zachary BessetteASCO GI 2024 | January 23, 2024
A novel combination regimen involving serplulimab may be a promising first-line treatment option for patients with mCRC.
Emily MenendezColorectal Cancer | January 23, 2024
Highest-grade differentiation may reduce the risk of misclassifying cases as negative.
Michael Lidsky, MDColorectal Cancer | January 23, 2024
Drs. Lidsky and Eng discuss PUMP, a phase 3 trial of HAI for treating patients with CRC and unresectable liver metastases.
Zachary BessetteColorectal Cancer | December 7, 2023
BMS announced that its phase 3 CheckMate 8HW trial in MSI-H or dMMR metastatic colorectal cancer met its primary end point.
Zachary BessetteColorectal Cancer | December 6, 2023
A retrospective cohort study examined the prevalence and reasons for an unsatisfactory FIT, a common CRC screening modality.
Marwan G. Fakih, MDColorectal Cancer | January 23, 2024
Dr. Fakih details his study and the results of the effectiveness of sotorasib plus panitumumab for KRAS G12C-mutated CRC.
Zachary BessetteColorectal Cancer | November 9, 2023
Fruquintinib is the first targeted agent in more than a decade for mCRC regardless of biomarker status or prior therapy.
Erica Barnell, MD, PhDColorectal Cancer | January 23, 2024
Dr. Barnell describes the "ColoSense" test and the study that showed its superior sensitivity and specificity vs colonoscopy.
Emily MenendezColorectal Cancer | November 3, 2023
Sotorasib plus panitumumab resulted in longer PFS than standard treatment, and toxic effects remained similar for each agent.
Katy MarshallColorectal Cancer | October 31, 2023
The trial analyzed the sensitivity and specificity of an mt-sRNA test compared with the results of a colonoscopy.
Katy MarshallColorectal Cancer | October 27, 2023
Researchers found no significant change in HRQOL and fatigue from randomization to 1 year.
Advertisement
Advertisement
Advertisement
Latest News

March 1, 2024